Kinetics of Soluble Mediators of the Host Response in Ebola Virus Disease

Journal of Infectious Diseases

Volumn 218, Issue , 2018, Pages S496-S503

  Kerber, Romy ^a,b   Krumkamp, Ralf ^a,b   Korva, Misa ^c   Rieger, Toni ^a,b   Wurr, Stephanie ^a,b   Duraffour, Sophie ^a,b   Oestereich, Lisa ^a,b   Gabriel, Martin ^a,b   Sissoko, Daouda ^d,e   Anglaret, Xavier ^d,e,f   Malvy, Denis ^d,e   May, Jürgen ^a,b   Zupanc, Tatjana Avšič ^c   Munoz Fontela C ^a,b   Günther, Stephan ^a,b  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^b Partner Sites Gießen Marburg Langen and Hamburg Borstel Lübeck Riems   (Germany)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f University Hospital of Treichville   (Côte d’Ivoire)

Author keywords

cytokines; Ebola virus disease; soluble mediators.

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLONY STIMULATING FACTOR 1; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FAS LIGAND; GRANZYME B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 3; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE 1; RANTES; THROMBOMODULIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 6; VASCULOTROPIN RECEPTOR 1; VON WILLEBRAND FACTOR; CHEMOKINE; CYTOKINE;

ADULT; BLOOD CLOTTING DISORDER; CELL ACTIVATION; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOTOXICITY; EBOLA HEMORRHAGIC FEVER; ENDOTHELIAL DYSFUNCTION; FEMALE; HOSPITAL ADMISSION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KINETICS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; SURVIVOR; T LYMPHOCYTE; BLOOD; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADULT; BIOMARKERS; CHEMOKINES; CROSS-SECTIONAL STUDIES; CYTOKINES; ENDOTHELIUM, VASCULAR; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; KINETICS; MALE; MIDDLE AGED; SURVIVORS; T-LYMPHOCYTES;

EID: 85057164998     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiy429     Document Type: Conference Paper

References (30)

1. Schieffelin JS, Shaffer JG, Goba A, et al.; KGH Lassa Fever Program; Viral Hemorrhagic Fever Consortium; WHO Clinical Response Team. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 2014; 371:2092-100.
2. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377:849-62.
3. Munoz-Fontela C, McElroy AK. Ebola Virus Disease in Humans: Pathophysiology and Immunity. Curr Top Microbiol Immunol 2017; 411:141-69.
4. McElroy AK, Harmon JR, Flietstra TD, et al. Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola Virus Disease. Clin Infect Dis 2016; 63:460-7.
5. McElroy AK, Erickson BR, Flietstra TD, et al. Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J Infect Dis 2014; 210:558-66.
6. Ruibal P, Oestereich L, Ludtke A, et al. Unique human immune signature of Ebola virus disease in Guinea. Nature 2016; 533:100-4.
7. Eisfeld AJ, Halfmann PJ, Wendler JP, et al. Multi-platform 'Omics analysis of human Ebola virus disease pathogenesis. Cell Host Microbe 2017; 22:817-29 e8.
8. Bixler SL, Goff AJ. The role of cytokines and chemokines in Filovirus infection. Viruses 2015; 7:5489-507.
9. Kerber R, Krumkamp R, Diallo B, et al. Analysis of diagnostic findings from the european mobile laboratory in Gueckedou, Guinea, March 2014 through March 2015. J Infect Dis 2016; 214:S250-S7.
10. Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol 2014; 5:491.
11. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011; 11:762-74.
12. Hutchinson KL, Rollin PE. Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J Infect Dis 2007; 196 (Suppl 2):S357-63.
13. Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163:2347-70.
14. McElroy AK, Erickson BR, Flietstra TD, et al. Von Willebrand factor is elevated in individuals infected with Sudan virus and is associated with adverse clinical outcomes. Viral Immunol 2015; 28:71-3.
15. Mohamadzadeh M, Chen L, Schmaljohn AL. How Ebola and Marburg viruses battle the immune system. Nat Rev Immunol 2007; 7:556-67.
16. McElroy AK, Erickson BR, Flietstra TD, et al. Biomarker correlates of survival in pediatric patients with Ebola virus disease. Emerg Infect Dis 2014; 20:1683-90.
17. Hensley LE, Young HA, Jahrling PB, Geisbert TW. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 2002; 80:169-79.
18. Fisher-Hoch SP, Platt GS, Neild GH, et al. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis 1985; 152:887-94.
19. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003; 188:1618-29.
20. van Paassen J, Bauer MP, Arbous MS, et al. Acute liver failure, multiorgan failure, cerebral oedema, and activation of proangiogenic and antiangiogenic factors in a case of Marburg haemorrhagic fever. Lancet Infect Dis 2012; 12:635-42.
21. Lyon GM, Mehta AK, Varkey JB, et al.; Emory Serious Communicable Diseases Unit. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014; 371:2402-9.
22. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978; 56:271-93.
23. Ksiazek TG, Rollin PE, Williams AJ, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999; 179(Suppl 1):S177-87.
24. Hunt L, Gupta-Wright A, Simms V, et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: An observational cohort study. Lancet Infect Dis 2015; 15:1292-9.
25. Skov Olsen P. Role of epidermal growth factor in gastroduodenal mucosal protection. J Clin Gastroenterol 1988; 10 (Suppl 1):S146-51.
26. Simmons G, Wool-Lewis RJ, Baribaud F, Netter RC, Bates P. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol 2002; 76:2518-28.
27. Zampieri CA, Fortin JF, Nolan GP, Nabel GJ. The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity. J Virol 2007; 81:1230-40.
28. McElroy AK, Akondy RS, Davis CW, et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci U S A 2015; 112:4719-24.
29. Cimini E, Viola D, Cabeza-Cabrerizo M, et al. Different features of V2 T and NK cells in fatal and non-fatal human Ebola infections. PLoS Negl Trop Dis 2017; 11:e0005645.
30. Dahlke C, Lunemann S, Kasonta R, et al. Comprehensive characterization of cellular immune responses following Ebola virus infection. J Infect Dis 2017; 215:287-92.